Drug Target Review

Insilico secures $888million Servier partnership for AI oncology

Explore how Insilico collaborates with Servier to advance AI-driven drug discovery in oncology for unmet medical needs.
EurekAlert!

Insilico Medicine announces US$888 million multi-year collaboration with Servier for drug discovery and development in oncology

Insilico Medicine (“Insilico”), a world-leading artificial intelligence (AI)-driven drug discovery company, today announced a ...
EurekAlert!

AI-powered RNA drug development: a new frontier in therapeutics

Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...
Drug Target Review

New Lumos AI platform targets precision in mental health drugs

Headlamp Health has launched Lumos AI®, a new decision-support platform designed to bring greater precision to neuroscience ...
GEN

Drug Discovery Innovation: Target Deconvolution and Tractability Assessment

Zhongyao Ma, PhD, holds a bachelor’s degree in biology from Shanghai Jiao Tong University and a PhD in genetics and developmental biology from the University of Georgia, U.S. His research focused on ...
MyHorryNews

Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology

Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico's AI-driven drug ...